anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Study participants in the pilot phase will include patients admitted to the Aberdeen Hospital Palliative Care Unit. Patients excluded from participating would include those unwilling to participate for any reason. All patients will be invited to complete the McGill Quality of Life Questionnaire - Revised (McGill QOL-R) upon admission to the unit. The Questionnaire will not be part of the permanent medical record and the participants will remain anonymous. Afterwards participants will be asked if they would like to listen to music during their stay in the hospital. Music will be selected according to their choices from an i-Tunes playlist. Participants will be invited to listen to music at their own discretion. Prior to discharge from the hospital or after 3 days all willing patients will be again invited to complete the McGill QOL-R questionnaire. The participants will remain anonymous, but will be identified as to whether they listened or did not listen to music during their hospitalization.
PROBLEM TO BE SOLVED: To reduce a burden of a user by smoothly carrying out a series of actions, i.e., an action from a hospital to a dispensing pharmacy and a delivery of a medicine dispensed by efficiently carrying out the delivery of the medicine dispensed, i.e., a final action with the user. SOLUTION: The receiving system is constituted by a server system communicatable with a user terminal and a facility terminal through a network. A facility registered as a user can receive a commodity beforehand is mapped on a map and is subjected to a data base. A time required for receiving the commodity at a receivable facility, etc., is calculated and the facility data is referred and retrieved by information selected/designated by a selection/ designation means. A facility data extracted by the retrieval means and a time calculated by the calculation means are transmitted to the user terminal. A receiving facility for receiving the commodity, etc., is instructed from the facility data indicated by an indication means. A predetermined data is transmitted to the receiving facility instructed by an instruction from the user terminal.
The present invention provides a rational basis for combining targeted therapies together with selected chemotherapeutics, which does not currently exist for the treatment of melanoma. The present invention is based on the present inventors' discovery that Akt3 regulates apoptosis and V599E B-Raf regulates growth and vascular development in melanoma. Inventors are the first to recognize an effective combined targeted therapeutic for treating melanoma.  In one embodiment, the invention provides a method for inducing apoptosis in a melanoma tumor cell by reducing Akt3 activity. In yet another embodiment, the invention provides a method for inducing apoptosis in a melanoma tumor cell comprising contacting a melanoma tumor cell with an agent that reduces Akt3 activity. Consequently, the method provided restores normal apoptotic sensitivity to a melanoma tumor cell, thereby allowing the administration of a lower concentration of chemotherapeutic agents resulting in decreased toxicity to a patient. The present inventors' contemplate a method for treating a melanoma tumor in a mammal comprising: administering to a melanoma tumor an effective amount of an agent to induce apoptosis; and administering to a melanoma tumor an effective amount of an agent to reduce angiogenesis and cell proliferation. Also disclosed herein is a method for treating a melanoma in a mammal comprising: administering to a melanoma tumor in a mammal an effective amount of an agent that reduces Akt3 activity; administering to a melanoma tumor in a mammal an effective amount of an agent that reduces V599E B-Raf activity, thereby treating a melanoma tumor. In another aspect, the invention provides a pharmaceutical composition for treating a melanoma tumor comprising: an agent that reduces Akt3 activity; and a carrier.
PURPOSE: Positive surgical margins (PSM) after robot-assisted radical prostatectomy (RARP) for prostate cancer (PCa) can increase the risk of biochemical recurrence and PCa-specific mortality. We aimed to evaluate the impact of multidisciplinary team meetings (MDTM) on reducing the incidence of PSM following RARP.
METHODS: We retrospectively collected the clinical data of consecutive patients undergoing RARP at Hiroshima University between February 2017 and October 2023. The MDTM, comprising a radiologist, uropathologist, and urologist, reviewed the preoperative magnetic resonance imaging (MRI) and prostate biopsy results of each patient before RARP and considered the areas requiring attention during RARP. Surgeons were categorized as experienced or non-experienced based on the number of RARP procedures performed.
RESULTS: In the pT2 population, the PSM rate was significantly lower in cases evaluated using the MDTM than in those not (11.1% vs. 24.0%; p = 0.0067). Cox regression analysis identified that a PSA level > 7 ng/mL (hazard ratio 2.2799) and nerve-sparing procedures (hazard ratio 2.2619) were independent predictors of increased PSM risk while conducting an MDTM (hazard ratio 0.4773) was an independent predictor of reduced PSM risk in the pT2 population. In the pathological T3 population, there was no significant difference in PSM rates between cases evaluated and not evaluated at an MDTM. In cases evaluated at an MDTM, similar PSM rates were observed regardless of surgeon experience (10.4% for non-experienced and 11.9% for experienced surgeons; p = 0.9999).
CONCLUSIONS: An MDTM can improve the PSM rate of pT2 PCa following RARP.
The annual burden of acute gastroenteritis in the United States includes 17 million related episodes and 473,832 hospitalizations. Although oral-rehydration therapy is recommended for children with mild-to-moderate dehydration, it has historically been underused with emergency department (ED) clinicians being more likely to choose intravenous over oral rehydration especially when vomiting is a major symptom. In fact, nearly 95% of children undergoing oral rehydration in Canadian EDs present with recent vomiting. To address this issue, the investigators conducted both a landmark clinical trial and a recent meta-analysis that have demonstrated that the ED use of ondansetron, an anti-emetic, leads to reductions in intravenous rehydration and hospitalization and is cost-effective. However, the available data revealed some associations with increased diarrhea and no evidence of benefits associated with ongoing ondansetron use following ED discharge. Despite the lack of available data, the provision of multiple doses of ondansetron for home use has become routine in many EDs across North America. The literature has differing opinions on the topic of ongoing ondansetron use after ED discharge and given the limited evidence supporting its use, the potential side effects and additional cost, there is an urgent need to definitively evaluate the effect of multiple doses of ondansetron in children, focusing on family-centred, post-index visit outcomes.

A phase III, double-blind, parallel-design, randomized, placebo controlled trial to compare multi-dose oral Ondansetron with placebo as treatment for vomiting secondary to acute gastroenteritis (AGE), after Emergency Department discharge will be conducted. Children and youth, age 6 months to 17.99 years will be enrolled at six (6) Canadian Emergency Departments. The total number of participants recruited will be 1030. Participants will be enrolled at six (6) pediatric emergency departments across Canada.

Children who are provided a minimum of one dose of ondansetron as part of their routine clinical care AND meet other eligibility criteria will be randomized to receive an at-home kit with six (6) doses of Ondansetron Hydrochloride Dihydrate Oral Solution (4mg/5mL solution; dosed at 0.15mg/kg to a maximum single dose of 8mg) or equivalent volume in a Placebo Oral Solution to be administered no sooner than 8 hours after the initial clinical dose was provided by the ED physician. Over the subsequent 48 hours, the study intervention will be administered at a rate of 1 dose every 8 hours (q8h) to a maximum of 3 doses a day (in a 24 hour period (TID)) at the caregiver's discretion. Two (2) additional doses will be provided to the caregiver in case the child vomits a dose.
The objective of this study is to compare the satisfaction of patients undergoing robot-assisted retroperitoneal laparoscopy adrenalectomy under the ambulatory mode and conventional mode. Basic information and clinical data of patients who underwent robotic-assisted posterior laparoscopic adrenalectomy between June 2020 and June 2023 were queried from our case system. The Outpatient and Ambulatory Surgery Consumer Assessment of Healthcare Providers and Systems Survey (OAS CAHPS®) was used to investigate patient satisfaction with preoperative preparation, discharge counseling, postoperative instructions, postoperative pain, and satisfaction with nursing work. The stats R package was used to select the appropriate statistic for the statistics based on the characteristics of the data. A total of 311 patients who underwent robot-assisted posterior laparoscopic adrenalectomy were enrolled in our case system. There were no statistical differences between the two groups in gender, age, body mass index, ASA classification, laterality, maximum tumor diameter, type of resection, hormonal activity, disease type, pathological classification, duration of surgery, estimated intraoperative bleeding, postoperative complications and follow-up period that were compared between the two groups of patients. There were no significant differences in preoperative preparation score, discharge counseling score, postoperative guidance score and nursing care satisfaction score (P > 0.05). Postoperative hospitalization, peristalsis time, defecation time, time to first postoperative mobilization, duration of indwelling drain and hospitalization costs in patients in the ambulatory model group were significantly less than patients in the conventional model group (P < 0.001). Patients in the ambulatory model group had significantly higher postoperative pain relief scores than patients in the conventional model group. In conclusion, our data suggest that patient satisfaction is equal between the conventional and ambulatory mode of performing robotic-assisted adrenalectomy. Patient satisfaction was probably associated with shorter hospitalization days, adequate preoperative preparation and standardized, high-quality post-discharge information and guidance.
The invention discloses a benfotiamine polymorphism body, a preparation method and an application of the benfotiamine polymorphism body. The benfotiamine polymorphism is the benfotiamine polymorphism of type A, the benfotiamine polymorphism of type B, the benfotiamine polymorphism of type C, the benfotiamine polymorphism of type D or the benfotiamine polymorphism of type E, which are different in x-ray powder diffraction drawings, DSC (Differential Scanning Calorimetry) crystals, infrared spectrums, Raman spectrums and preparation methods. The invention also provides the application of the benfotiamine polymorphism body in the preparation of medicines for treating vitamin B deficiency, relative metabolic disturbance, various mental diseases, abalienation, relative diabetic complications and neurodegenerative disease. According to the preparation method, the benfotiamine of different polymorphism types are purified by different synthetic technologies and then are converted into the benfotiamine polymorphism of type A, the benfotiamine polymorphism of type B, the benfotiamine polymorphism of type C, the benfotiamine polymorphism of type D and the benfotiamine polymorphism of type E under a crystallizing mode based on different matching ratios of the solvents. Various polymorphism types are basically in pure crystallizing form. The invention provides a new polymorphism form of the benfotiamine, and also provides a solvent compound of the benfotiamine, and in particular provides an aquo-complex of the benfotiamine.
Lamotrigine, USP an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine’s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine, its molecular formula is C9H7N5Cl2, and its molecular weight is 256.1. Lamotrigine is a white or almost white powder and has a pKa of 5.7. Lamotrigine is slightly soluble in anhydrous ethanol and in 0.1M hydrochloric acid. The structural formula is:  
  
Lamotrigine extended-release tablets, USP are supplied for oral administration as 200 mg, blue, round, biconvex film-coated tablets; 250 mg, purple, caplet shaped, biconvex film-coated tablets; and 300 mg, grey, caplet shaped, biconvex film-coated tablets. Each tablet contains the labeled amount of lamotrigine and the following inactive ingredients: lactose monohydrate, povidone K-30, hypromellose, colloidal silicon dioxide, magnesium stearate, methacrylic acid and ethyl acrylate copolymer, silicon dioxide, triethyl citrate, titanium dioxide, polyethylene glycol 400, ferrosoferric oxide (250 mg and 300 mg tablets only), FD&C Blue No. 2 Aluminum Lake (200 mg and 250 mg tablets only), carmine (250 mg tablet only). Tablets are imprinted with edible black ink containing shellac, propylene glycol and ferrosoferric oxide. 

  


Lamotrigine extended-release tablets, USP contains modified-release, erodible matrix as the core. The core tablet is coated with a modified enteric coat to enable a controlled release of drug in the acidic environment of the stomach. The combination of the modified-release core and the modified enteric coating are designed to control the dissolution rate of lamotrigine over a period of approximately 12 to 15 hours, leading to a gradual increase in serum lamotrigine levels.  
  
FDA approved dissolution testing specifications differ from USP.
Cervical cancer is a leading cause of cancer-related death among women and its recurrence and metastasis poses challenges to treatment. Discoidin domain receptor 1 (DDR1) was associated with cellular migration and invasion in several types of cancers. However, its function in cervical cancer is still unclear. In this study, we found that DDR1 was significantly more expressed in cervical cancer samples than in normal tissues. SRY-Box transcription factor 2 (SOX2), a known oncogene in cervical cancer, showed a positive correlation with DDR1 and regulated DDR1 transcription, contributing to the elevated expression of DDR1 in cervical cancer. Regarding the function of DDR1 in cervical cancer, the overexpression of DDR1 caused an increase in the migration, invasion, and epithelial-mesenchymal transition (EMT) of cervical cancer cells. In contrast, cervical cancer cells with reduced DDR1 expression exhibited a lower migration rate, fewer invasive cells, and decreased levels of EMT markers. In vivo, mice injected with cervical cancer cells with overexpressed DDR1 showed more pulmonary metastasis and nodule number. Opposite results were found in mice injected with DDR1 silenced cervical cancer cells. Since DDR1 can cause phosphorylation of downstream targets, a phosphorylation omics was employed to reveal the downstream targets of DDR1, including eukaryotic translation initiation factor 4E binding protein 1 and EPH receptor A2. Furthermore, DDR1 bound directly with Src homology 2 domain of growth factor receptor bound protein 2 (GRB2) which mediated the function of DDR1 in the malignant behaviors of cervical cancer and the phosphorylation of downstream targets. In conclusion, DDR1 binds directly to GRB2 and then affects downstream phosphorylation signals, ultimately exacerbating the metastasis of cervical cancer cells. This work sheds light on the mechanism by which DDR1 functions in cervical cancer cells, providing therapeutic strategy for the treatment of cervical cancer.
The invention provides a chlormethine compound with double activity function groups and application of the chlormethine compound serving as an anti-tumor drug. A structure of the compound is shown in the specification. In-vitro anti-tumor experiments prove that the compound has good inhibiting effect on liver cancer cells of the human body. In-vitro deoxyribose nucleic acid (DNA) crosslinking experiments prove that the compound has good crosslinking effects on plasmid DNA. Mouse analgesia experiments prove that the compound has good analgesia effects. The chlormethine compound is simple in synthesizing steps and good in anti-tumor effects, possibly simulates the analgesia effects of acetaminophen in vivo, is an anti-tumor drug with double functions, and has great medical value.
Tardive dyskinesia, a syndrome of potentially irreversible, involuntary, dyskinetic movements, may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible appear to increase as the duration of treatment and the total cumulative dose. The syndrome can develop after relatively brief treatment periods, even at low doses. It may also occur after discontinuation of treatment.

Tardive dyskinesia may remit, partially or completely, if antipsychotic treatment is discontinued. Antipsychotic treatment itself may suppress (or partially suppress) the signs and symptoms of the syndrome and may thus mask the underlying process. The effect of symptomatic suppression on the long-term course of the syndrome is unknown.

Given these considerations, INVEGA HAFYERA should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that is known to respond to antipsychotic drugs. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient treated with INVEGA HAFYERA, drug discontinuation should be considered. Consideration should be given to the long-acting nature of INVEGA HAFYERA. However, some patients may require treatment with INVEGA HAFYERA despite the presence of the syndrome.
PURPOSE: To tightly coat the surface of a base material with an apatite layer by incorporating at least Au and Ca as alloy constituting elements into an alloy. CONSTITUTION: Gold bullion and calcium bullion are put in an alumina crucible by 10g and 1.5g, respectively, they are held at 1,100 deg.C for 20 min in an atmosphere of gaseous Ar and then quenching is carried out. The resultant alloy has three kinds of quenched phases different from one another in the ratio of Au:Ca in a mixed state and the average concn. of Ca in the alloy is 11.5wt.%. This alloy is used as the objective material for an implant. An Au-Ca alloy as a material for an implant practically contains 80-99.5wt.% Au and 0.5-20wt.% Ca. The surface of the alloy is coated with an apatite layer and an implant capable of withstanding practical use can be provided.
Colonoscopy screening is a preventative measure for colorectal carcinoma (CRC), a highly malignant and dangerous cancer. Extensive research on the adenoma detection rate has provided national standards and quality metrics to help assess competence of endoscopists. Currently, there are no standards established for serrated adenomas. The proposed study would be conducted at Good Samaritan Hospital (GSH) and TriHealth Surgery Center West. This is an observational study and does not involve any patient interventions. However, because patient healthcare data will be collected for research, informed consent will be obtained shortly before the procedure. The main study objective is to determine the detection rate of serrated adenoma during screening colonoscopy at our institution. Additionally, the variability of serrated adenoma detection among endoscopists will be evaluated and the characteristics of serrated adenomas will be described.
Compositions and methods relating to DNase fusion polypeptides are disclosed. The fusion polypeptides include a biologically active DNase joined to the amino-terminus of an immunoglobulin Fc region via a flexible polypeptide linker (e.g., a linker containing at least 26 amino acid residues). Typically, the DNase is a hyperactive and/or actin-resistant DNase1 variant (e.g., a variant of human DNase1 having one or more amino acid substitutions selected from substitutions at Asp-53, Tyr-65, Glu-69, Arg-74, Gly-105, and Ala-114 according to amino acid position numbering of mature wild-type human DNase1) or a DNase1L3 variant (e.g., a variant of human DNase1L3 in which the native nuclear localization signals are removed). In some embodiments, the fusion polypeptide includes a polypeptide segment located carboxyl-terminal to the Fc region and which may be, e.g., a biologically active paraoxonase. Also disclosed are dimeric proteins comprising first and second DNase fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy, including methods for treating diseases and disorders characterized by NETosis.
The invention relates to clopidogrel hydrogen sulphate tablets. The clopidogrel hydrogen sulphate tablets are prepared from the following raw materials in percentage by weight: 30-43% of clopidogrel hydrogen sulfate, 15-45% of diluents, 5-30% of disintegrant, 0.1-8% of lubricant, 0.1-2% of glidants and 1-4% of powder for coating. The tablets are dissolved rapidly and released uniformly. The invention also relates to a preparation method of the clopidogrel hydrogen sulphate tablets. The preparation method comprises the following steps of mixing, tabletting and coating. The preparation method is simple and practicable; and the quality of prepared finished products is stable.
Systems and methods for routing prescription drug claims between a pharmacy and a plurality of pharmacy benefit managers (PBMs). The systems and methods implemented by one or more processing circuits. One method includes receiving a prescription drug claim from the pharmacy, the prescription drug claim comprising routing information that causes the pharmacy to send the prescription drug claim to the prescription drug claim routing system. The method further includes obtaining a set of rules for routing the prescription drug claim. The method further includes selecting a PBM from the plurality of PBMs by applying the set of rules to the prescription drug claim. The method further includes modifying the routing information of the prescription drug claim to include updated routing information corresponding to the selected PBM and sending the prescription drug claim to the selected PBM for processing in accordance with the updated routing information.